Clinical Trial Update: Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the combination of Oblimersen with Imatinib Mesylate in patients with chronic myelogenous leukemia, including BCR-ABL1-positive and ot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia
• Myelogenous Leukemia Bcr-abl1 Positive

Drugs mentioned

• Imatinib Mesylate (Gleevec) (Imatinib mesylate)
• Oblimersen (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED